Limits...
MS14 down-regulates lipocalin2 expression in spinal cord tissue in an animal model of multiple sclerosis in female C57BL/6.

Ebrahimi-Kalan A, Soleimani Rad J, Kafami L, Mohammadnejad D, Habibi Roudkenar M, Khaki AA, Aliyari Serej Z, Mohammadi Roushandeh A - Iran. Biomed. J. (2014)

Bottom Line: Recently, it has been proved that MS14, an herbal-marine drug, has anti-inflammatory properties through reduction of TNF-α and IL-1β.On 21st and 35th days after immunization, mice (n = 4/group) were deeply anesthetized, and the spinal cords were removed.MS14 significantly ameliorated EAE symptoms and decreased lymphocyte infiltration into the spinal cord (P<0.05).

View Article: PubMed Central - PubMed

Affiliation: Dept. of Anatomical Sciences, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. a.mohammadiroshandeh@umsha.ac.ir.

ABSTRACT

Background: Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis, which is a demyelinating and an inflammatory disease of central nervous system. Recent studies have established that some molecules such as Lipocaline2 (LCN2), which expresses during inflammatory conditions, play an important role in EAE pathogenesis and might involve in its treatment process. Recently, it has been proved that MS14, an herbal-marine drug, has anti-inflammatory properties through reduction of TNF-α and IL-1β. Thus, the present study investigated the effects of MS14 on the course of EAE and its relation to LCN2 expression in both protein and gene levels.

Methods: EAE was induced in female C57BL/6 mice using Hooke kits. Animals were scored for clinical signs of the disease according to a 10-point EAE scoring system. On 21st and 35th days after immunization, mice (n = 4/group) were deeply anesthetized, and the spinal cords were removed. Inflammatory cell infiltration and LCN2 expression in spinal cord were assessed by hematoxylin and eosin staining, immuno-histochemistry, and real-time PCR methods.

Results: MS14 significantly ameliorated EAE symptoms and decreased lymphocyte infiltration into the spinal cord (P<0.05). Our data also revealed that LCN2 expression was significantly down-regulated in acute and chronic phases of EAE both at protein and gene levels after MS14 treatment (P<0.05).

Conclusion: The results demonstrated that MS14 regulatory effect on EAE is accompanied by LCN2 down-regulation after treatment with the herb; however, more studies are required for clarifying the other involved mechanisms.

Show MeSH

Related in: MedlinePlus

Effects of MS14 on daily clinical score of EAE during 35 days after immunization. Daily clinical score of MS14-treated group was compared to control group using Mann Whitney test. Values are shown as means ± SEM. MS14 suppressed significantly the signs of the disease from 22 days after immunization to the end (*P<0.05). Open (○) and black circles (●) represent mean daily clinical score for MS14-treated and control groups, respectively. Asterisk shows significant difference
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4225058&req=5

Figure 1: Effects of MS14 on daily clinical score of EAE during 35 days after immunization. Daily clinical score of MS14-treated group was compared to control group using Mann Whitney test. Values are shown as means ± SEM. MS14 suppressed significantly the signs of the disease from 22 days after immunization to the end (*P<0.05). Open (○) and black circles (●) represent mean daily clinical score for MS14-treated and control groups, respectively. Asterisk shows significant difference

Mentions: MS14-reduced clinical signs of the experimental autoimmune encephalomyelitis. MS14 significantly decreased the daily clinical score of the disease at effector phase of the disease (P<0.05, days 22-35 after immunization, Fig. 1). Cumulative disease index showed MS14-treated animals (36.43 ± 4.8) had lower EAE severity than the control animals (53.25 ± 4.88) (P<0.05). The rate of clinical score at chronic phase of the disease (day 30 to 35 after immunization) was significantly lower in MS14-treated group compared to controls (P<0.05, Fig. 1). Time to EAE onset was detected approximately on day 12 after immunization and reached to a peak stage on day 21 after immunization, where the most animals remained ill (score 2.5-3) throughout the entire experimental period (35 days after immunization, Fig. 1). MS14 neither affected clinical scores at the peak of the disease nor delayed time to EAE onset significantly. Animals were weighted once a week during the experiment, but there was not observed significantly any difference between the groups.


MS14 down-regulates lipocalin2 expression in spinal cord tissue in an animal model of multiple sclerosis in female C57BL/6.

Ebrahimi-Kalan A, Soleimani Rad J, Kafami L, Mohammadnejad D, Habibi Roudkenar M, Khaki AA, Aliyari Serej Z, Mohammadi Roushandeh A - Iran. Biomed. J. (2014)

Effects of MS14 on daily clinical score of EAE during 35 days after immunization. Daily clinical score of MS14-treated group was compared to control group using Mann Whitney test. Values are shown as means ± SEM. MS14 suppressed significantly the signs of the disease from 22 days after immunization to the end (*P<0.05). Open (○) and black circles (●) represent mean daily clinical score for MS14-treated and control groups, respectively. Asterisk shows significant difference
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4225058&req=5

Figure 1: Effects of MS14 on daily clinical score of EAE during 35 days after immunization. Daily clinical score of MS14-treated group was compared to control group using Mann Whitney test. Values are shown as means ± SEM. MS14 suppressed significantly the signs of the disease from 22 days after immunization to the end (*P<0.05). Open (○) and black circles (●) represent mean daily clinical score for MS14-treated and control groups, respectively. Asterisk shows significant difference
Mentions: MS14-reduced clinical signs of the experimental autoimmune encephalomyelitis. MS14 significantly decreased the daily clinical score of the disease at effector phase of the disease (P<0.05, days 22-35 after immunization, Fig. 1). Cumulative disease index showed MS14-treated animals (36.43 ± 4.8) had lower EAE severity than the control animals (53.25 ± 4.88) (P<0.05). The rate of clinical score at chronic phase of the disease (day 30 to 35 after immunization) was significantly lower in MS14-treated group compared to controls (P<0.05, Fig. 1). Time to EAE onset was detected approximately on day 12 after immunization and reached to a peak stage on day 21 after immunization, where the most animals remained ill (score 2.5-3) throughout the entire experimental period (35 days after immunization, Fig. 1). MS14 neither affected clinical scores at the peak of the disease nor delayed time to EAE onset significantly. Animals were weighted once a week during the experiment, but there was not observed significantly any difference between the groups.

Bottom Line: Recently, it has been proved that MS14, an herbal-marine drug, has anti-inflammatory properties through reduction of TNF-α and IL-1β.On 21st and 35th days after immunization, mice (n = 4/group) were deeply anesthetized, and the spinal cords were removed.MS14 significantly ameliorated EAE symptoms and decreased lymphocyte infiltration into the spinal cord (P<0.05).

View Article: PubMed Central - PubMed

Affiliation: Dept. of Anatomical Sciences, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. a.mohammadiroshandeh@umsha.ac.ir.

ABSTRACT

Background: Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis, which is a demyelinating and an inflammatory disease of central nervous system. Recent studies have established that some molecules such as Lipocaline2 (LCN2), which expresses during inflammatory conditions, play an important role in EAE pathogenesis and might involve in its treatment process. Recently, it has been proved that MS14, an herbal-marine drug, has anti-inflammatory properties through reduction of TNF-α and IL-1β. Thus, the present study investigated the effects of MS14 on the course of EAE and its relation to LCN2 expression in both protein and gene levels.

Methods: EAE was induced in female C57BL/6 mice using Hooke kits. Animals were scored for clinical signs of the disease according to a 10-point EAE scoring system. On 21st and 35th days after immunization, mice (n = 4/group) were deeply anesthetized, and the spinal cords were removed. Inflammatory cell infiltration and LCN2 expression in spinal cord were assessed by hematoxylin and eosin staining, immuno-histochemistry, and real-time PCR methods.

Results: MS14 significantly ameliorated EAE symptoms and decreased lymphocyte infiltration into the spinal cord (P<0.05). Our data also revealed that LCN2 expression was significantly down-regulated in acute and chronic phases of EAE both at protein and gene levels after MS14 treatment (P<0.05).

Conclusion: The results demonstrated that MS14 regulatory effect on EAE is accompanied by LCN2 down-regulation after treatment with the herb; however, more studies are required for clarifying the other involved mechanisms.

Show MeSH
Related in: MedlinePlus